The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy

PHASE4WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions
HypertensionIntracranial HemorrhageSubarachnoid Hemorrhage
Interventions
DRUG

Clevidipine butyrate

Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.

Trial Locations (1)

38104

Methodist Healthcare, University Hospital, Memphis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

The Medicines Company

INDUSTRY

lead

Methodist Healthcare

OTHER